Literature DB >> 21547272

Diabetes prevalence estimates in schizophrenia and risk factor assessment.

Tami Argo1, Ryan Carnahan, Mitchell Barnett, Timothy L Holman, Paul J Perry.   

Abstract

BACKGROUND: Atypical antipsychotics have been indirectly associated with the diagnosis of type 2 diabetes mellitus (T2DM) in patients with schizophrenia. The purpose of this cross-sectional study was to determine the prevalence of T2DM and to examine the risk factors associated with T2DM among outpatients diagnosed with schizophrenia. The study also sought to determine which risk factors are of particular screening importance in monitoring the metabolic status of these patients.
METHODS: This study included 202 patients diagnosed with schizophrenia. Data on a number of known and hypothesized risk factors for T2DM were collected.
RESULTS: Risk factors for T2DM identified by bivariate analyses in this sample included older age, waist-to-hip ratio >1.0, sedentary lifestyle, number of hours worked per week, hyperlipidemia, previous screening for T2DM, higher random blood glucose, and number of years on atypical antipsychotics risperidone or olanzapine. However, further scrutiny using multiple logistic regression identified only sedentary lifestyle, waist-to-hip ratio ≥1.0, and a diagnosis of hyperlipidemia as significant risk factors in these patients. Similar to other studies, there was an 11.5% (22/192) lifetime prevalence rate of diabetes among this population.
CONCLUSIONS: Risk factors traditionally associated with T2DM, as well as waist-to-hip ratio, are the factors most strongly associated with increased risk of diabetes in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547272

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  6 in total

Review 1.  Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.

Authors:  Ellen M Janssen; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Gen Hosp Psychiatry       Date:  2015-03-14       Impact factor: 3.238

2.  Socio-environmental factors associated with diabetes mellitus among patients hospitalized with schizophrenia in Japan.

Authors:  Junya Sado; Tetsuhisa Kitamura; Norio Noma; Makiko Saito; Hitoshi Azuma; Tsukasa Azuma; Tomotaka Sobue; Yuri Kitamura
Journal:  Environ Health Prev Med       Date:  2016-07-22       Impact factor: 3.674

3.  GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice.

Authors:  Brend Ray-Sea Hsu; Shin-Huei Fu
Journal:  Toxicol Rep       Date:  2016-04-27

4.  Identifying multimodal signatures underlying the somatic comorbidity of psychosis: the COMMITMENT roadmap.

Authors:  Emanuel Schwarz; Dag Alnæs; Ole A Andreassen; Han Cao; Junfang Chen; Franziska Degenhardt; Daria Doncevic; Dominic Dwyer; Roland Eils; Jeanette Erdmann; Carl Herrmann; Martin Hofmann-Apitius; Tobias Kaufmann; Nikolaos Koutsouleris; Alpha T Kodamullil; Adyasha Khuntia; Sören Mucha; Markus M Nöthen; Riya Paul; Mads L Pedersen; Andres Quintero; Heribert Schunkert; Ashwini Sharma; Heike Tost; Lars T Westlye; Youcheng Zhang; Andreas Meyer-Lindenberg
Journal:  Mol Psychiatry       Date:  2020-10-15       Impact factor: 15.992

Review 5.  A polygenic score for schizophrenia predicts glycemic control.

Authors:  Han Cao; Junfang Chen; Andreas Meyer-Lindenberg; Emanuel Schwarz
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

6.  The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.

Authors:  Yangyu Zhang; Yingyu Liu; Yingying Su; Yueyue You; Yue Ma; Guang Yang; Yan Song; Xinyu Liu; Mohan Wang; Lili Zhang; Changgui Kou
Journal:  BMC Psychiatry       Date:  2017-11-21       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.